TheraRadar
← Back
Data updated: Jun 28, 2026

LEO PHARMA AS

Big Pharma
ImmunologyDermatologyOncology Execution: Excellent

LEO PHARMA AS is a major pharmaceutical company focused on Immunology, Dermatology, Oncology. Key products include ADBRY.

1993
Since
9
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
5 Small Molecules 1 Biologics

FDA Novel Drug Designations

(2021-2025)
2 Novel 1 First-in-Class 1 Fast Track
See 2 novel approvals →
2025 ANZUPGO (DELGOCITINIB) Fast Track
2021 ADBRY (TRALOKINUMAB) First-in-Class

LEO PHARMA AS at a Glance

  • Strong track record with 90% execution quality across 172 trials
  • Fast trial execution (9 months median completion)

LEO PHARMA AS's Key Drugs

LEO PHARMA AS's core commercial portfolio centers on ANZUPGO, ADBRY, ENSTILAR, spanning Immunology and Dermatology — its most strategically important drugs approved in the last 15 years.

ANZUPGO
Dermatology

Chronic Hand Eczema

JAK1 Approved 2025
ADBRY
Immunology

Atopic Dermatitis

IL-13 Approved 2021
ENSTILAR
Immunology

Plaque Psoriasis

Glucocorticoid receptor Approved 2015

LEO PHARMA AS's Recent FDA Approvals

LEO PHARMA AS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

ANZUPGO NDA
2025-07-23
delgocitinib
Chronic Hand Eczema

LEO PHARMA AS's Therapeutic Areas

LEO PHARMA AS's approved drugs and pipeline span 4 therapeutic areas, led by Immunology and Dermatology, across 1 biologic and 5 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 50%
2 drugs Phase 3: 15 Phase 2: 20 Phase 1: 24
Dermatology 48%
2 drugs Phase 3: 17 Phase 2: 16 Phase 1: 19
Oncology 1%
0 drugs Phase 3: 1
Metabolic 0%
0 drugs Phase 1: 1

LEO PHARMA AS's Top Competitors

LEO PHARMA AS's closest competitors by therapeutic-area and drug-target overlap include Eli Lilly, Pfizer, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Dermatology
Pfizer big-pharma
Oncology, Immunology, Dermatology
Baxter specialty
Oncology, Dermatology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Metabolic
GSK big-pharma
Oncology, Immunology, Metabolic

LEO PHARMA AS Pipeline Snapshot

LEO PHARMA AS has 113 active clinical programs from ClinicalTrials.gov — 33 Phase 3, 36 Phase 2 and 44 Phase 1.

33
Phase 3
36
Phase 2
44
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • ANZUPGO leads revenue
  • • 3 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Immunology pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 39/44 completed
  • • Speed: 9 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges